Intermittent Systematic Chemotherapy, Metastatic Nasopharyngeal Carcinoma
Conditions
Keywords
metastatic nasopharyngeal carcinoma, systematic chemotherapy, intermittent systematic chemotherapy
Brief summary
This study aimed to investigate the value of a novel strategy of intermittent systematic chemotherapy (ISC) in widely metastatic nasopharyngeal carcinoma (wmNPC) patients who achieve objective response after systematic chemotherapy (SC).
Detailed description
Widely metastatic nasopharyngeal carcinoma (wmNPC) represented a particular subgroup of patients with the worst prognosis, of which palliative systematic chemotherapy(SC) was recommended as initial treatment, however, palliative systematic treatment was often required to be stopped due to the cumulative toxicities while stopping SC may lead to disease progression, a 'stop and go' approach, namely chemotherapy 'holidays', was a new strategy which may keep a good balance of benefit and risk. This study aimed to investigate the value of a novel strategy of intermittent systematic chemotherapy (ISC) in wmNPC patients who achieve objective response after SC.
Interventions
DRUGGemcitabine
1000 mg/m2 on Days 1 and 8
DRUGCisplatin
a total of 80-100 mg/m2 for d1-3
260 mg/m2 on Day 1
DRUGCapecitabine
a dose of 1-1.25 g/m2 twice daily in in 2 weeks for one cycle
DRUGTislelizumab
200 mg on Day 1
Sponsors
Fujian Cancer Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with multiple metastases at first diagnosis or multiple metastases after treatment(multiple metastases were defined as more than 5 lesions and/or more than 2 metastasis organs); Histologically or cytologically confirmed multiple metastatic NPC. 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 at trial entry, and life expectancy ≥ 6 months as judged by the Investigator; 3. The disease must be measurable with at least 1 unidimensional measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; Adequate organ function; 4. Take adequate contraceptive measures throughout the study, and contraception continues until 12 months after treatment; 5. Able and willing to provide a signed informed consent form, and able to comply with all procedures. 6. The time from the last chemotherapy and/or radiotherapy to randomization must be ≥6 months.
Exclusion criteria
1. Patients with a hypersensitivity to any of the drugs used in our study; 2. With any active autoimmune disease or history of autoimmune disease; 3. Clinically significant cardiovascular and cerebrovascular diseases; 4. Have or are suffering from other malignant tumors within 5 years (except non-melanoma skin cancer or pre-invasive cervical cancer); 5. Active systemic infection; 6. Drug or alcohol abuse; 7. No or limited capacity for civil conduct; 8. The patient has a physical or mental disorder, and the researcher considers that the patient is unable to fully or fully understand the possible complications of this study; 9. History of immunodeficiency including seropositive for human immunodeficiency virus (HIV), or other acquired or congenital immune-deficient disease, or any active systemic viral infection requiring therapy； 10. Use cortisol or other systematic immunosuppressive medications within 4 weeks before the study treatment, and the subject requiring hormone therapy during trials. 11. Pregnancy or breastfeeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| progression-free survival | 1 year | the time interval from the start of chemotherapy to the date of progression |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| progression-free survival 2 | 1 year | the time interval from the start of chemotherapy to the date of wide progression |
| overall survival | 1 year | time from the date of the start of chemotherapy to death due to any cause |
Contacts
Primary ContactShaojun Lin, DR
Outcome results
None listed